clinical trial · NCT06524375
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
Genentech, Inc.·phase2·active not recruiting·n = 118
Chronic Lymphocytic LeukemiaVenetoclaxcBTKi Monotherapy
brief summary
The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD \< or 10\^-4 in peripheral blood (PB)\] by end of combination treatment (EOCT) to allow off-treatment period. The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment periods) with VEnetoclax.
started
Aug 9, 2024
primary completion
Oct 31, 2026
completion
Jan 31, 2030
last updated
Sep 28, 2026
official title
Phase II, Open-label, Prospective Single-arm, Multi-center Clinical Trial to Evaluate if Adding Venetoclax to Patients on Covalent BTKi For 1L CLL Can Achieve Deep Durable Remissions (by UMRD 10^-4) to Allow Off-treatment Period
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol